Skip to content

Adherence and implementation

TL;DR — This is the central problem of the condition: the pharmacology has worked for fifty years and global control rates are 23% in women and 18% in men (NCD-RisC 2021, PMID 34450083). What moves population control is system redesign, not new molecules. A village-doctor-led protocol in 326 Chinese villages and 33,995 people raised control to <130/80 mm Hg from 19.9% to 57.0% at 18 months (group difference 37.0 percentage points, 95% CI 34.9–39.1) with a 14.5 mm Hg systolic separation (Sun 2022, PMID 35500594). A pharmacist-led intervention delivered in 52 Black-owned barbershops lowered systolic pressure 21.6 mm Hg more than an active control (95% CI 14.7–28.4) and achieved <130/80 mm Hg in 63.6% versus 11.7% (Victor 2018, PMID 29527973). A non-physician-health-worker model in Colombia and Malaysia produced an 11.45 mm Hg greater systolic reduction and control in 69% versus 30% (Schwalm 2019, PMID 31488369). And Kaiser Permanente Northern California raised control from 43.6% to 80.4% between 2001 and 2009 with a registry, shared metrics, medical-assistant blood-pressure visits and single-pill combinations, while the national mean rose from 55.4% to 64.1% (Jaffe 2013, PMID 23989679). None of these required a new drug.

The size of the gap

Metric Value Source
Global control among people with hypertension, 2019 23% women, 18% men (NCD-RisC 2021, PMID 34450083)
Cascade in 44 LMICs 73.6% measured → 39.2% diagnosed → 29.9% treated → 10.3% controlled (Geldsetzer 2019, PMID 31327566)
US control, 2013–2014 → 2017–2018 53.8% → 43.7% (Muntner 2020, PMID 32902588)
US control with vs without a healthcare visit in the past year 49.1% vs 8.0% (adjusted PR 5.23, 95% CI 2.88–9.49) (Muntner 2020, PMID 32902588)
Non-adherence in apparent treatment-resistant hypertension 31.2% (95% CI 20.2–44.7) pooled (Durand 2017, PMID 28777133)
Complete non-adherence by chemical testing 15.0% pooled; 33.0% for any non-adherence (Highton 2025, PMID 40371625)

Measuring adherence

Method determines the answer. Self-report and pharmacy refill records systematically understate non-adherence relative to liquid chromatography–tandem mass spectrometry of urine or serum, or directly observed therapy — the single strongest source of heterogeneity in the meta-analyses (Durand 2017, PMID 28777133; Highton 2025, PMID 40371625; da Luz Pádua Guimarães 2026, PMID 42564271). Biochemical testing is not only diagnostic: feeding results back was associated with blood-pressure reduction and improved adherence (Gupta 2017, PMID 28847892), and routine urinary detection has been deployed at scale in a hypertension unit (Hamdidouche 2017, PMID 28505066). It has been applied in hypertensive crisis presentations (Wallbach 2019, PMID 30515967) and in heart failure, where non-adherence predicted outcomes (Gupta 2021, PMID 33759308). Chemical testing has so far been used overwhelmingly in tertiary care and in predominantly White populations, which limits what is known about its equity (Highton 2025, PMID 40371625). Adherence in a real-world pragmatic trial has been examined directly (Hynes 2025, PMID 40869531), and non-adherence is a common contributor to uncontrolled hypertension generally (Kulkarni 2021, PMID 33832064).

Interventions that work

Task-shifting and team-based care

Study Setting Design Result
CRHCP (PMIDs 35500594, 36871573, 42666029) 326 rural Chinese villages, 33,995 people Cluster RCT; village doctors initiate and titrate by protocol under physician supervision, plus home monitoring and coaching Control <130/80: 57.0% vs 19.9% at 18 months. At 3 years, cardiovascular events were 1.62% vs 2.40%/year (HR 0.67, 95% CI 0.61–0.73) and all-cause death HR 0.85 (0.76–0.95). Over 7 years, cardiovascular events were 2.4% vs 3.0%/year (HR 0.76, 0.72–0.81), with hypotension RR 1.58 (1.39–1.79)
Barbershop trial (PMID 29527973) 52 Black-owned barbershops, 319 Black men Cluster RCT; pharmacist prescribing under collaborative practice agreement vs barber-promoted lifestyle and appointments Systolic −27.0 vs −9.3 mm Hg (difference 21.6, 95% CI 14.7–28.4); <130/80 in 63.6% vs 11.7%; 95% retention; 3 cases of acute kidney injury
HOPE 4 (PMID 31488369) 30 communities, Colombia and Malaysia, 1,371 people Cluster RCT; non-physician health workers with tablet-based algorithms, free medicines, a family treatment supporter Systolic −11.45 mm Hg greater (95% CI −14.94 to −7.97); control <140 mm Hg 69% vs 30%; Framingham 10-year risk −4.78 percentage points greater
Kaiser Permanente Northern California (PMID 23989679) Integrated system, 652,763 registry patients by 2009 Before–after with external comparison Control 43.6% → 80.4% vs national mean 55.4% → 64.1%

Community Guide systematic reviews confirm the generality: team-based care raised the proportion controlled by a median of 12 percentage points and lowered systolic pressure by a median 5.4 mm Hg across 80 studies, with the largest effects when pharmacists and nurses were team members (Proia 2014, PMID 24933494), and it is economically favourable (Jacob 2015, PMID 26477804; Jacob 2023, PMID 37121447). Pharmacist interventions specifically improve control (Santschi 2014, PMID 24721801), and pharmacist prescribing is cost-effective in the US (Dixon 2023, PMID 37921763). Nurse-led interventions have their own meta-analyses (Stephen 2022, PMID 35244944; Bulto 2024, PMID 37130339). The barbershop effect was largely sustained at 12 months (Victor 2019, PMID 30592662), with qualitative and commentary literature on transferability (Blyler 2019, PMID 31425171; Ebinger 2020, PMID 32562103; Bryant 2020, PMID 32180133; Kohrman 2024, PMID 38723012).

CRHCP now has the hard-outcome evidence that the 2022 control report lacked. At 36 months the primary cardiovascular composite was 1.62% versus 2.40% per year (HR 0.67, 95% CI 0.61–0.73), with reductions in myocardial infarction, stroke, heart-failure admission, cardiovascular death and all-cause death, offset by more hypotension (1.75% vs 0.89%) (He 2023, PMID 36871573). Seven-year follow-up, including three years after withdrawal of free/discounted medication, extra training and performance incentives, retained a 13.5 mm Hg systolic separation and lower cardiovascular-event rates both overall (HR 0.76, 0.72–0.81) and post-trial (0.79, 0.73–0.85); hypotension (RR 1.58, 1.39–1.79) and mild hypokalaemia (1.38, 1.23–1.56) were more frequent (Sun 2026, PMID 42666029).

Simplifying the regimen

Fixed-dose combinations act on adherence rather than on physiology. Individual-participant meta-analysis of TIPS-3, HOPE-3 and PolyIran (18,162 participants, median 5 years) found the primary cardiovascular composite in 3.0% versus 4.9% (HR 0.62, 95% CI 0.53–0.73), with reductions in myocardial infarction (0.52, 0.38–0.70), revascularisation (0.54, 0.36–0.80), stroke (0.59, 0.45–0.78) and cardiovascular death (0.65, 0.52–0.81); benefits were larger when aspirin was included, gastrointestinal bleeding was uncommon (0.4% vs 0.2%), and dizziness was more frequent (11.7% vs 9.2%) (Joseph 2021, PMID 34469765). TIPS-3 itself randomised a polypill with or without aspirin in primary prevention (Yusuf 2021, PMID 33186492). The low-dose triple and quarter-dose quadruple combination strategies belong here as much as to pharmacology — see pharmacological therapy (Webster 2018, PMID 30120478; Chow 2021, PMID 34469767). Reducing medication cost-sharing is itself an intervention with Community Guide evidence (Njie 2015, PMID 26605708), and cost-related non-adherence remains prevalent in the US (Reddy 2025, PMID 40285540; Piette 2006, PMID 16765278).

Self-monitoring — only with a co-intervention

Self-monitoring alone does not lower blood pressure: −1.0 mm Hg (95% CI −3.3 to 1.2) unaccompanied versus −6.1 mm Hg (−9.0 to −3.2) with intensive support in individual-participant meta-analysis of 25 trials (Tucker 2017, PMID 28926573). TASMINH2 and TASMINH4 supply the interventional versions with titration built in (McManus 2010, PMID 20619448; McManus 2018, PMID 29499873; Bray 2015, PMID 25566874), and both are cost-effective (Kaambwa 2014, PMID 23990660; Monahan 2019, PMID 31067190). How often self-monitoring should be repeated and what regimen to use have been analysed from those trials (Rose 2025, PMID 40838357; Morris 2025, PMID 40407130), and qualitative work covers acceptability (Grant 2019, PMID 31262847). Digital interventions — apps and text messaging — show modest effects (Kassavou 2022, PMID 35819830; Jubayer 2024, PMID 39182005). Economics of self-measured monitoring has its own Community Guide review (Jacob 2017, PMID 28818277).

Protocols and policy

Standardised treatment protocols are the connective tissue of every successful programme above. Their global availability and alignment with guideline recommendations have been surveyed, and both are patchy (Satheesh 2024, PMID 38108382). The WHO HEARTS framework operationalises this, and its policy implications for the Americas have been set out (Campbell 2022, PMID 35711684); Hypertension Canada's 2025 guideline is explicitly built on it (Goupil 2025, PMID 40419299). System-level analyses show country preparedness indicators predict quality of care across 44 LMICs (Davies 2020, PMID 33170842), and scoping reviews map where cascades leak (Wang 2024, PMID 38149840). Implementation trials in HIV care and other integrated settings test the same logic (Gimbel 2020, PMID 32143657).

What has not worked, and why it matters

The US control rate rose to 53.8% by 2013–2014 and then fell to 43.7% by 2017–2018 (Muntner 2020, PMID 32902588) — during a period of expanding generic availability and intensified guideline attention. Whether NHANES is representative of that trajectory has been argued (Egan 2023, PMID 37967159), but the direction is not disputed elsewhere: comorbidity burden among people with hypertension rose, and control of hypertension plus diabetes plus hyperlipidaemia together has been stuck at about one quarter for more than a decade (Lee 2025, PMID 41295934). Young adults are the worst-served group: 5.6% controlled among those aged 18–39 with stage 1/2 hypertension, with routine-care-source differences explaining only 7–16% of the age gap (Tang 2025, PMID 40156902).

The general pattern across the successful trials is that they replaced clinician discretion with a protocol, moved the point of care to where the patient already was, and removed a cost or access barrier. None of them relied on patient education alone.

Open questions

  • The CRHCP, barbershop and HOPE 4 effects are among the largest in the hypertension literature. What is the active ingredient — protocolised titration, non-physician prescribing authority, location, free medication, or the treatment supporter? The 2026-09-01 searches located factorial implementation trials in adjacent settings but none decomposing these three programmes' components (Sun 2022, PMID 35500594; Victor 2018, PMID 29527973; Schwalm 2019, PMID 31488369).
  • Kaiser's programme was observational with an external comparator (Jaffe 2013, PMID 23989679). Which of its components would survive randomisation?
  • Should biochemical adherence testing be routine before treatment escalation, given that it changes management in a third of apparently resistant patients? (Durand 2017, PMID 28777133; Gupta 2017, PMID 28847892)
  • Why did US control fall after 2014 despite cheaper drugs and lower thresholds? (Muntner 2020, PMID 32902588; Lee 2025, PMID 41295934)
  • Polypill trials for primary prevention combine blood-pressure and lipid lowering; how much of the 38% relative risk reduction is attributable to the antihypertensive component, and does it matter for policy? (Joseph 2021, PMID 34469765)

References

  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control. Lancet. 2021;398:957-980. PMID 34450083
  2. Sun Y, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China. Lancet. 2022;399:1964-1975. PMID 35500594
  3. Victor RG, et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. N Engl J Med. 2018;378:1291-1301. PMID 29527973
  4. Schwalm JD, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4). Lancet. 2019;394:1231-1242. PMID 31488369
  5. Jaffe MG, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310:699-705. PMID 23989679
  6. Geldsetzer P, et al. The state of hypertension care in 44 low-income and middle-income countries. Lancet. 2019;394:652-662. PMID 31327566
  7. Muntner P, et al. Trends in Blood Pressure Control Among US Adults With Hypertension. JAMA. 2020;324:1190-1200. PMID 32902588
  8. Durand H, et al. Medication adherence among patients with apparent treatment-resistant hypertension. J Hypertens. 2017;35:2346-2357. PMID 28777133
  9. Highton PJ, et al. Chemical Adherence Testing for Assessing Adherence to Antihypertensive Medications. Behav Med. 2025;51:265-279. PMID 40371625
  10. da Luz Pádua Guimarães MC, et al. Prevalence of adherence to antihypertensive treatment: drug biochemical analysis vs self-report. Clin Hypertens. 2026;32:e37. PMID 42564271
  11. Gupta P, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70:1042-1048. PMID 28847892
  12. Hamdidouche I, et al. Routine urinary detection of antihypertensive drugs. J Hypertens. 2017;35:1891-1898. PMID 28505066
  13. Wallbach M, et al. Direct assessment of adherence and drug interactions in patients with hypertensive crisis. J Clin Hypertens. 2019;21:55-63. PMID 30515967
  14. Gupta P, et al. Non-adherence to heart failure medications predicts clinical outcomes. Eur J Heart Fail. 2021;23:1182-1190. PMID 33759308
  15. Hynes CA, et al. Medication Adherence in the Real World: Lessons from the Diuretic Comparison Project. J Clin Med. 2025;14. PMID 40869531
  16. Kulkarni S, et al. Nonadherence to antihypertensive medications amongst patients with uncontrolled hypertension. Medicine (Baltimore). 2021;100:e24654. PMID 33832064
  17. Proia KK, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86-99. PMID 24933494
  18. Jacob V, et al. Economics of Team-based Care in Controlling Blood Pressure. Am J Prev Med. 2015;49:772-783. PMID 26477804
  19. Jacob V, et al. Economics of Team-Based Care for Blood Pressure Control: Updated Community Guide Systematic Review. Am J Prev Med. 2023;65:735-754. PMID 37121447
  20. Santschi V, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis. J Am Heart Assoc. 2014;3:e000718. PMID 24721801
  21. Dixon DL, et al. Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States. JAMA Netw Open. 2023;6:e2341408. PMID 37921763
  22. Stephen C, et al. Nurse-led interventions to manage hypertension in general practice: systematic review and meta-analysis. J Adv Nurs. 2022;78:1281-1293. PMID 35244944
  23. Bulto LN, et al. Effectiveness of nurse-led interventions versus usual care to manage hypertension and lifestyle behaviour. Eur J Cardiovasc Nurs. 2024;23:21-32. PMID 37130339
  24. Victor RG, et al. Sustainability of Blood Pressure Reduction in Black Barbershops. Circulation. 2019;139:10-19. PMID 30592662
  25. Blyler CA, et al. Sustainability of blood pressure reduction in black barbershops. Curr Opin Cardiol. 2019;34:693-699. PMID 31425171
  26. Ebinger J, et al. Barbershop Management of Hypertension in the African American Population. Curr Cardiol Rep. 2020;22:64. PMID 32562103
  27. Bryant KB, et al. It's Time for a Haircut: a Perspective on Barbershop Health Interventions Serving Black Men. J Gen Intern Med. 2020;35:3057-3059. PMID 32180133
  28. Kohrman N, et al. A qualitative analysis of post-hoc interviews with multilevel participants of a randomized controlled trial. PLoS One. 2024;19:e0303075. PMID 38723012
  29. Joseph P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention: individual participant data meta-analysis. Lancet. 2021;398:1133-1146. PMID 34469765
  30. Yusuf S, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease (TIPS-3). N Engl J Med. 2021;384:216-228. PMID 33186492
  31. Webster R, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care (TRIUMPH). JAMA. 2018;320:566-579. PMID 30120478
  32. Chow CK, et al. Initial treatment with a single pill containing quadruple combination of quarter doses (QUARTET). Lancet. 2021;398:1043-1052. PMID 34469767
  33. Njie GJ, et al. Reducing Medication Costs to Prevent Cardiovascular Disease: A Community Guide Systematic Review. Prev Chronic Dis. 2015;12:E208. PMID 26605708
  34. Reddy RV, et al. Cost-related medication nonadherence in adults with hypertension in the USA. Int J Qual Health Care. 2025;37. PMID 40285540
  35. Piette JD, et al. Medication characteristics beyond cost alone influence decisions to underuse pharmacotherapy. J Clin Epidemiol. 2006;59:739-46. PMID 16765278
  36. Tucker KL, et al. Self-monitoring of blood pressure in hypertension: individual patient data meta-analysis. PLoS Med. 2017;14:e1002389. PMID 28926573
  37. McManus RJ, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2). Lancet. 2010;376:163-72. PMID 20619448
  38. McManus RJ, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring (TASMINH4). Lancet. 2018;391:949-959. PMID 29499873
  39. Bray EP, et al. Performance and persistence of a blood pressure self-management intervention (TASMINH2). J Hum Hypertens. 2015;29:436-41. PMID 25566874
  40. Kaambwa B, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis. Eur J Prev Cardiol. 2014;21:1517-30. PMID 23990660
  41. Monahan M, et al. Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration (TASMINH4). Hypertension. 2019;73:1231-1239. PMID 31067190
  42. Rose F, et al. How often should self-monitoring of blood pressure be repeated? J Hypertens. 2025;43:1863-1870. PMID 40838357
  43. Morris EC, et al. The importance of experience: insights into optimal home-blood pressure monitoring regimens from TASMINH4. J Hypertens. 2025;43:1400-1406. PMID 40407130
  44. Grant S, et al. Using mHealth for the management of hypertension in UK primary care: embedded qualitative study of TASMINH4. Br J Gen Pract. 2019;69:e612-e620. PMID 31262847
  45. Kassavou A, et al. The Association Between Smartphone App-Based Self-monitoring of Hypertension-Related Behaviors and Reductions in High Blood Pressure. JMIR Mhealth Uhealth. 2022;10:e34767. PMID 35819830
  46. Jubayer S, et al. Text messaging to improve retention in hypertension care in Bangladesh. J Hum Hypertens. 2024;38:765-771. PMID 39182005
  47. Jacob V, et al. Economics of Self-Measured Blood Pressure Monitoring: A Community Guide Systematic Review. Am J Prev Med. 2017;53:e105-e113. PMID 28818277
  48. Satheesh G, et al. Standardized treatment protocols for hypertension: global availability, characteristics, and alignment with guideline recommendations. J Hypertens. 2024;42:902-908. PMID 38108382
  49. Campbell NRC, et al. 2021 WHO guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas. Lancet Reg Health Am. 2022;9. PMID 35711684
  50. Goupil R, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197:E549-E564. PMID 40419299
  51. Davies JI, et al. Association between country preparedness indicators and quality clinical care for cardiovascular disease risk factors in 44 LMICs. PLoS Med. 2020;17:e1003268. PMID 33170842
  52. Wang J, et al. Understanding Gaps in the Hypertension and Diabetes Care Cascade: Systematic Scoping Review. JMIR Public Health Surveill. 2024;10:e51802. PMID 38149840
  53. Gimbel S, et al. Systems analysis and improvement approach to optimize the hypertension diagnosis and care cascade for PLHIV. Implement Sci. 2020;15:15. PMID 32143657
  54. Egan BM, et al. Trends in Hypertension Control Among United States Adults: Is NHANES the Outlier? Hypertension. 2023;80:2544-2546. PMID 37967159
  55. Lee HH, et al. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension. J Am Coll Cardiol. 2025;86:2577-2593. PMID 41295934
  56. Tang R, et al. Trends in Hypertension Prevalence, Awareness, Treatment, and Control Among US Young Adults. Am J Hypertens. 2025;38:551-559. PMID 40156902
  57. He J, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP). Lancet. 2023;401:928-938. PMID 36871573
  58. Sun G, et al. Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial. Circulation. 2026. PMID 42666029